Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)

• Status: Not yet recruiting
• Trial end date: 2024-04-11
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety and efficacy of IMM0306-02 in patients with refractory or relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd
• Collaborator: Worldwide Clinical Trials

Criteria

Inclusion Criteria:

• 18-75 years old

• Diagnosed with B-NHL

• Relapsed after or be refractory to at least 2 line of standard therapy

Exclusion Criteria:

• Active central nervous system (CNS) metastases

• Positive Direct Antiglobulin Test (DAT)

• Active autoimmune disorder

• Skin disorders that do not requires hormone replacement therapy